Genitourinary Reconstructive Surgery Division, Department of Urology, Hospital Italiano de Buenos Aires, Pres. Tte. Gral. Juan Domingo Perón 4190, C1199 ABH, Buenos Aires, Argentina.
Laser and Endourology Division, Department of Urology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
World J Urol. 2024 Oct 25;42(1):594. doi: 10.1007/s00345-024-05306-5.
To evaluate the technical feasibility, safety, and patency results of a simultaneous surgical approach to repair urethral stricture and treat benign prostatic enlargement endoscopically in a highly selected group of patients at a tertiary referral center. We hypothesize that this is technically feasible, safe, and does not affect urethroplasty outcomes.
A retrospective review of adult men who underwent simultaneous urethroplasty and endoscopic prostatic surgery between May 2017 and May 2024 at our institution was conducted. Patients with strictures < 15 French and prostates with adverse prognostic features of response to medical treatment were included. The primary outcome was technical feasibility and safety. The secondary outcome was stricture-free survival.
Twenty men were treated during the study period. The median length of the urethral stricture was 3.0 cm (IQR 2.0-5.0), and the median size of the prostate was 95.0 cc (IQR 63.3-128.3). All patients were treated successfully with a median operative time of 194.5 min (IQR 180.0-246.8), and no procedures required conversion to a staged procedure or open prostatectomy. There were seven Clavien-Dindo I-II complications and one Clavien-Dindo IIIb complication (hematuria requiring endoscopic clot evacuation). At 22 months follow-up, two cases of urethral re-stricture were diagnosed, with one case requiring redo urethroplasty, though none had previous major complications.
The combination of urethroplasty and endoscopic surgery for benign prostatic enlargement at the same stage appears to be technically viable and safe, and it does not compromise medium-term urethral patency results in a carefully selected group of patients.
在一家三级转诊中心,评估一种在高度选择的患者群体中同时进行尿道狭窄修复和经内镜前列腺切除术的技术可行性、安全性和通畅结果。我们假设这种方法在技术上是可行的、安全的,并且不会影响尿道成形术的结果。
对 2017 年 5 月至 2024 年 5 月期间在我院接受同时进行尿道成形术和内镜前列腺手术的成年男性进行了回顾性研究。纳入的患者为狭窄长度<15Fr 和前列腺对药物治疗反应具有不良预后特征的患者。主要结局是技术可行性和安全性。次要结局是无狭窄生存。
研究期间共治疗了 20 名男性。尿道狭窄的中位长度为 3.0cm(IQR 2.0-5.0),前列腺的中位大小为 95.0cc(IQR 63.3-128.3)。所有患者均成功接受治疗,中位手术时间为 194.5 分钟(IQR 180.0-246.8),无任何手术需要转换为分期手术或开放性前列腺切除术。有 7 例 Clavien-Dindo I-II 级并发症和 1 例 Clavien-Dindo IIIb 级并发症(血尿需行内镜血块清除术)。22 个月随访时,诊断出 2 例尿道再狭窄,其中 1 例需要再次行尿道成形术,但均无先前的严重并发症。
在高度选择的患者群体中,同期进行尿道成形术和内镜手术似乎在技术上是可行的和安全的,并且不会影响中期尿道通畅结果。